ibrutinib,rituximab
abbvie,janssen
[' ibru']
excellent plenary session on autosct vs auto+ibr vs ibr in mcl. os data yet to emerge but this could be practice changing. but let s not forget med access, tox, and adherence to ibrutinib in real world pts vs clinical trials!
#ash22 
Assistant Professor at UNC Eshelman School of Pharmacy. #adherence, #leukemia, #globalhealth, #access, #impsci, #equity